Alan F. Schatzberg, M.D. Dr. Schatzberg's research examines the biology and psychopharmacology of depressive disorders. Past studies include norepinephrine systems in depression as a means of subtyping, the development of delusions in major depression, and the clinical pharmacology of nondelusional depression with a focus on chronic depression. He was elected into the Institute of Medicine of the National Academy of Sciences in 2003, and he holds co-editor, editorial board, or presidential positions with several journals and societies.

Positions

• Kenneth T. Norris, Jr., Professor, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
• Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine

Education

• M.D., 1968, New York University School of Medicine, Medicine

Relevant Publications

• Reynolds CF, Lewis DA, Detre T, Schatzberg AF, Kupfer DJ. The future of psychiatry as clinical neuroscience. Acad Med. 2009;84(4):446-450.
• Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res. 2009;43(5):512-518.
• Killen J, Fortmann S, Schatzberg A, et al. Extended cognitive behavior therapy for cigarette smoking cessation. Addiction. 2008;103(8):1381-1390.
• Keller J, Shen L, Gomez R, Garrett A, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Am J Psychiatry. 2008;165(7):872-880.
• Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(suppl 8):26-34.